FibroGen Wins Big Upfront, Keeps US Rights to Oral Anemia Drug
Executive Summary
Astellas Pharma badly wanted to expand its rights to FibroGen's oral anemia compounds beyond Japan. So badly, in fact, that it paid a whopping $300 million up front, agreed to up to $465 million in pre-approval milestones, and will fund half of the compounds' development in Europe and North America. Yet Astellas doesn't even get North American commercial rights in exchange: it had to settle for European and other ex-US territories.
You may also be interested in...
Promedior and Stromedix Spot Fresh Approaches in Fibrosis
New approaches to treating fibrotic disorders have led to start-up financing for Promedior and Stromedix, two biotechs with early-stage in-licensed large molecule programs. To succeed where others have so-far failed the two newcomers will need innovative clinical strategies to accelerate their paths to proof-of-concept.
Can Amgen Find a New Engine?
Amgen's string of misfortunes has highlighted the group's need to find an alternative growth engine--one which will, necessarily, look very different from the current anemia franchise. The biotech is leaning too heavily on osteoporosis and cancer candidate denosumab.
Can Amgen Find a New Engine?
Amgen's string of misfortunes has highlighted the group's need to find an alternative growth engine--one which will, necessarily, look very different from the current anemia franchise. The biotech is leaning too heavily on osteoporosis and cancer candidate denosumab.